1. Home
  2. PBYI vs IDE Comparison

PBYI vs IDE Comparison

Compare PBYI & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • IDE
  • Stock Information
  • Founded
  • PBYI 2010
  • IDE 2010
  • Country
  • PBYI United States
  • IDE United States
  • Employees
  • PBYI N/A
  • IDE N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • IDE Finance/Investors Services
  • Sector
  • PBYI Health Care
  • IDE Finance
  • Exchange
  • PBYI Nasdaq
  • IDE Nasdaq
  • Market Cap
  • PBYI 176.1M
  • IDE 159.4M
  • IPO Year
  • PBYI N/A
  • IDE N/A
  • Fundamental
  • Price
  • PBYI $2.32
  • IDE $10.48
  • Analyst Decision
  • PBYI Strong Buy
  • IDE
  • Analyst Count
  • PBYI 1
  • IDE 0
  • Target Price
  • PBYI $7.00
  • IDE N/A
  • AVG Volume (30 Days)
  • PBYI 393.6K
  • IDE 33.5K
  • Earning Date
  • PBYI 10-31-2024
  • IDE 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • IDE 8.83%
  • EPS Growth
  • PBYI N/A
  • IDE N/A
  • EPS
  • PBYI 0.18
  • IDE N/A
  • Revenue
  • PBYI $219,143,000.00
  • IDE N/A
  • Revenue This Year
  • PBYI N/A
  • IDE N/A
  • Revenue Next Year
  • PBYI N/A
  • IDE N/A
  • P/E Ratio
  • PBYI $12.75
  • IDE N/A
  • Revenue Growth
  • PBYI N/A
  • IDE N/A
  • 52 Week Low
  • PBYI $2.13
  • IDE $8.61
  • 52 Week High
  • PBYI $7.73
  • IDE $10.46
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 34.73
  • IDE 46.35
  • Support Level
  • PBYI $2.23
  • IDE $10.32
  • Resistance Level
  • PBYI $2.56
  • IDE $10.72
  • Average True Range (ATR)
  • PBYI 0.17
  • IDE 0.15
  • MACD
  • PBYI -0.01
  • IDE -0.04
  • Stochastic Oscillator
  • PBYI 14.06
  • IDE 25.41

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: